Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

NCT06096844 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06096844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06096844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Recruiting
Start date
July 19, 2024
Completion date
April 1, 2039
Enrollment
304 (estimated)
Sites
326

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lung non-small cell carcinoma, stage iiib lung cancer ajcc v8, stage iiic lung cancer ajcc v8, stage iv lung cancer ajcc v8